{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:26:29Z","timestamp":1760549189248},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ejpb.2011.12.011","type":"journal-article","created":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T12:59:46Z","timestamp":1325336386000},"page":"621-629","source":"Crossref","is-referenced-by-count":32,"title":["New oral solid dosage form for furosemide oral administration"],"prefix":"10.1016","volume":"80","author":[{"given":"Luana","family":"Perioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"D\u2019Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2011.12.011_b0005","first-page":"23","volume":"vol. 121","author":"Marshall","year":"1990"},{"key":"10.1016\/j.ejpb.2011.12.011_b0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1134\/S1990750808030037","article-title":"The biopharmaceutical classification system-experimental model of prediction of drug bioavailability","volume":"2","author":"Golovenko","year":"2008","journal-title":"Biochem. Suppl. Ser. B: Biomed. Chem."},{"key":"10.1016\/j.ejpb.2011.12.011_b0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0378-5173(00)00344-6","article-title":"Biopharmaceutics and pharmacokinetics in drug research","volume":"201","author":"Panchagnula","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.12.011_b0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.addr.2007.05.006","article-title":"Oral lipid-based formulations","volume":"59","author":"Hauss","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2011.12.011_b0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of the essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2011.12.011_b0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1359-6446(04)03351-3","article-title":"Formulation strategies for absorption windows","volume":"10","author":"Davis","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2011.12.011_b0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/17425247.2.3.419","article-title":"Strategies to improve oral drug bioavailability","volume":"2","author":"Gomez-Orellana","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2011.12.011_b0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10717540601098823","article-title":"Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery","volume":"14","author":"Heikkil\u00e4","year":"2007","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2011.12.011_b0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.micromeso.2011.07.007","article-title":"MCM-41 for furosemide dissolution improvement","volume":"147","author":"Ambrogi","year":"2012","journal-title":"Micropor. Mesopor. Mater."},{"key":"10.1016\/j.ejpb.2011.12.011_b0050","first-page":"265","article-title":"Nanotechnology and drug delivery Part 1: background and applications","volume":"8","author":"Ochekpe","year":"2009","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.12.011_b0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clay.2006.06.010","article-title":"Layered double hydroxides and human health: an overview","volume":"36","author":"Del Hoyo","year":"2007","journal-title":"Appl. Clay Sci."},{"key":"10.1016\/j.ejpb.2011.12.011_b0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clay.2006.07.007","article-title":"Clay minerals and layered double hydroxides for novel biological applications","volume":"36","author":"Choy","year":"2007","journal-title":"Appl. Clay Sci."},{"key":"10.1016\/j.ejpb.2011.12.011_b0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijantimicag.2006.11.019","article-title":"Nanohybrids for controlled antibiotic release in topical applications","volume":"29","author":"Tammaro","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2011.12.011_b0070","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jps.10411","article-title":"Effect of hydrotalcite like-compounds on the aqueous solubility of some poorly water soluble drugs","volume":"92","author":"Ambrogi","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.12.011_b0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.clay.2010.12.019","article-title":"Effects of hydrotalcite-like nanostructured compounds on biopharmaceutical properties and release of BCS class II drugs: the case of flurbiprofen","volume":"51","author":"Perioli","year":"2011","journal-title":"Appl. Clay Sci."},{"key":"10.1016\/j.ejpb.2011.12.011_b0080","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.clay.2011.06.006","article-title":"Preformulation studies on host-guest composites for the oral administration of BCS class IV drugs: HTlc and furosemide","volume":"53","author":"Perioli","year":"2011","journal-title":"Appl. Clay Sci."},{"key":"10.1016\/j.ejpb.2011.12.011_b0085","unstructured":"R.F. Stockel, Bisphosphonates Inorganic Carriers, US Patent 0013893A1, 2006."},{"key":"10.1016\/j.ejpb.2011.12.011_b0090","series-title":"Pharmaceutical Powder Compaction Technology","first-page":"420","author":"Bolhus","year":"1996"},{"key":"10.1016\/j.ejpb.2011.12.011_b0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.micromeso.2007.02.005","article-title":"Hydrotalcite-like compounds: versatile layered hosts of molecular anions with biological activity","volume":"107","author":"Costantino","year":"2008","journal-title":"Micropor. Mesopor. Mater."},{"issue":"3","key":"10.1016\/j.ejpb.2011.12.011_b0100","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1208\/pt0803054","article-title":"Mucoadhesive bilayered tablets for buccal sustained release of flurbiprofen","volume":"8","author":"Perioli","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2011.12.011_b0105","series-title":"Layered Double Hydroxides and their Intercalation Compounds in Photochemistry and Medicinal Chemistry, Layered Double Hydroxides: Present and Future","first-page":"435","author":"Costantino","year":"2001"},{"key":"10.1016\/j.ejpb.2011.12.011_b0110","series-title":"Remington. The Science and Practice of Pharmacy","first-page":"893","author":"Rudnic","year":"2005"},{"key":"10.1016\/j.ejpb.2011.12.011_b0115","first-page":"501","article-title":"Effect of compression force, humidity and disintegrant concentration on the disintegration and dissolution of directly compressed furosemide tablets using croscarmellose sodium as disintegrant","volume":"2","author":"Andries","year":"2003","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.ejpb.2011.12.011_b0120","first-page":"52","article-title":"Coprocessed excipients for solid dosage forms","volume":"1","author":"Nachaegari","year":"2004","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.ejpb.2011.12.011_b0125","series-title":"Handbook of Pharmaceutical Excipients","first-page":"501","year":"2000"},{"key":"10.1016\/j.ejpb.2011.12.011_b0130","series-title":"Handbook of Pharmaceutical Excipients","first-page":"163","year":"2000"},{"issue":"2","key":"10.1016\/j.ejpb.2011.12.011_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1208\/pt030211","article-title":"Powder and mechanical properties of microcrystalline cellulose with different degrees of polymerization","volume":"3","author":"Shlieout","year":"2002","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.ejpb.2011.12.011_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/ps050431","article-title":"Properties of microcrystalline cellulose and powder cellulose after extrusion\/spheronization as studied by Fourier transform Raman spectroscopy and environmental scanning electron microscopy","volume":"5","author":"Fechner","year":"2003","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ejpb.2011.12.011_b0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(98)00127-6","article-title":"Physicochemical comparison between microcrystalline cellulose and silicified microcrystalline cellulose","volume":"169","author":"Tobyn","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.12.011_b0150","first-page":"46","article-title":"An overview of the effect of moisture on compaction and compression","volume":"29","author":"Nokhodchi","year":"2005","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.ejpb.2011.12.011_b0155","series-title":"Handbook of Pharmaceutical Excipients","first-page":"555","year":"2000"},{"key":"10.1016\/j.ejpb.2011.12.011_b0160","first-page":"58","article-title":"An overview of the different excipients useful for the direct compression of tablets","volume":"3","author":"Jivraj","year":"2000","journal-title":"PSTT"},{"issue":"Suppl.","key":"10.1016\/j.ejpb.2011.12.011_b0165","article-title":"Orally disintegrating tablets. The effect of recent FDA guidance on ODT technologies applications","author":"McLaughlin","year":"2009","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.ejpb.2011.12.011_b0170","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Guidance for Industry Orally Disintegrating Tablets, 2008."},{"key":"10.1016\/j.ejpb.2011.12.011_b0175","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jps.22030","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: furosemide","volume":"99","author":"Granero","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.12.011_b0180","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1039\/B204076J","article-title":"Intercalation chemistry of layered double hydroxides: recent developments and applications","volume":"12","author":"Khan","year":"2002","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.ejpb.2011.12.011_b0185","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clay.2010.11.027","article-title":"Dissolution of nano-size Mg\u2013Al\u2013Cl hydrotalcite in aqueous media","volume":"51","author":"Jobb\u00e1gy","year":"2011","journal-title":"Appl. Clay Sci."},{"key":"10.1016\/j.ejpb.2011.12.011_b0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2005.11.041","article-title":"Evaluation of rapidly disintegrating tablets containing glycine and carboxymethylcellulose","volume":"310","author":"Fukami","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.12.011_b0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0378-5173(79)90095-4","article-title":"Gastrointestinal sites of furosemide absorption in rats","volume":"4","author":"Chungi","year":"1979","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.12.011_b0200","unstructured":"L. Perioli, V. Ambrogi, C. Pagano, M. Nocchetti, G. D\u2019Alba, C. Rossi, Farmaci di classe IV del BCS: un approccio tecnologico-formulativo per migliorare le propriet\u00e0 biofarmaceutiche, 50\u00b0 Simposio AFI 23, 2010 pp. 277\u2013278."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111003699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111003699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T05:26:56Z","timestamp":1543296416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641111003699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0939641111003699"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2011.12.011","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}